Published in Hepatology on November 01, 2009
Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med (2013) 3.35
Evolving therapies for liver fibrosis. J Clin Invest (2013) 2.59
Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin α(V)β(3) engagement and PI3K/pAkt/NFκB signaling. Hepatology (2012) 1.40
Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci (2011) 1.39
Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Gastrointest Liver Physiol (2011) 1.24
Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology (2011) 1.17
Integrin-mediated regulation of TGFβ in fibrosis. Biochim Biophys Acta (2012) 1.12
Loss of myeloid cell-derived vascular endothelial growth factor accelerates fibrosis. Proc Natl Acad Sci U S A (2010) 1.03
Aquaporin-1 facilitates angiogenic invasion in the pathological neovasculature that accompanies cirrhosis. Hepatology (2010) 0.98
Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. World J Gastroenterol (2010) 0.96
Fibrinogen deficiency increases liver injury and early growth response-1 (Egr-1) expression in a model of chronic xenobiotic-induced cholestasis. Am J Pathol (2011) 0.95
Integrins αvβ5 and αvβ3 promote latent TGF-β1 activation by human cardiac fibroblast contraction. Cardiovasc Res (2014) 0.90
Cannabinoid receptor type I modulates alcohol-induced liver fibrosis. Mol Med (2011) 0.89
Vascular factors, angiogenesis and biliary tract disease. Curr Opin Gastroenterol (2010) 0.88
Specific hepatic delivery of procollagen α1(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosis. Hepatology (2015) 0.85
Involvement of cholangiocyte proliferation in biliary fibrosis. World J Gastrointest Pathophysiol (2010) 0.83
Increased activation of latent TGF-β1 by αVβ3 in human Crohn's disease and fibrosis in TNBS colitis can be prevented by cilengitide. Inflamm Bowel Dis (2013) 0.83
Aquaporin-1 promotes angiogenesis, fibrosis, and portal hypertension through mechanisms dependent on osmotically sensitive microRNAs. Am J Pathol (2011) 0.83
Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis. PLoS One (2013) 0.83
Integrins and integrin-related proteins in cardiac fibrosis. J Mol Cell Cardiol (2015) 0.80
Adenosine 5'-monophosphate ameliorates D-galactosamine/lipopolysaccharide-induced liver injury through an adenosine receptor-independent mechanism in mice. Cell Death Dis (2014) 0.79
Microvascular targets for anti-fibrotic therapeutics. Yale J Biol Med (2013) 0.78
Combination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in rats. BMC Gastroenterol (2015) 0.78
Hepatic macrophages in liver fibrosis: pathogenesis and potential therapeutic targets. BMJ Open Gastroenterol (2016) 0.78
Prevention of liver fibrosis by intrasplenic injection of high-density cultured bone marrow cells in a rat chronic liver injury model. PLoS One (2014) 0.77
Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease. Am J Physiol Renal Physiol (2011) 0.77
Mechanisms of adaptation of the hepatic vasculature to the deteriorating conditions of blood circulation in liver cirrhosis. World J Hepatol (2016) 0.77
Angiogenesis and Fibrogenesis in Chronic Liver Diseases. Cell Mol Gastroenterol Hepatol (2015) 0.76
αv integrins: key regulators of tissue fibrosis. Cell Tissue Res (2016) 0.76
Editorial Commentary: Understanding Marfan syndrome, or "how not to invent the light bulb". Trends Cardiovasc Med (2016) 0.75
Protective Effects of Norursodeoxycholic Acid Versus Ursodeoxycholic Acid on Thioacetamide-induced Rat Liver Fibrosis. J Clin Exp Hepatol (2014) 0.75
Fibrin-mediated integrin signaling plays a critical role in hepatic regeneration after partial hepatectomy in mice. Ann Hepatol (2016) 0.75
Reduction of hepatic fibrosis by overexpression of von Hippel-Lindau protein in experimental models of chronic liver disease. Sci Rep (2017) 0.75
αvβ1 integrin as a novel therapeutic target for tissue fibrosis. Ann Transl Med (2016) 0.75
Future therapy of portal hypertension in liver cirrhosis - a guess. F1000Prime Rep (2014) 0.75
A new technique to improve the mechanical and biological performance of ultra high molecular weight polyethylene using a nylon coating. J Mech Behav Biomed Mater (2014) 0.75
Ex vivo expansion of circulating CD34(+) cells enhances the regenerative effect on rat liver cirrhosis. Mol Ther Methods Clin Dev (2016) 0.75
Molecular magnetic resonance imaging of activated hepatic stellate cells with ultrasmall superparamagnetic iron oxide targeting integrin αvβ3 for staging liver fibrosis in rat model. Int J Nanomedicine (2016) 0.75
Integrins and heparan sulfate proteoglycans on hepatic stellate cells (HSC) are novel receptors for HSC-derived exosomes. FEBS Lett (2016) 0.75
Placental growth factor silencing ameliorates liver fibrosis and angiogenesis and inhibits activation of hepatic stellate cells in a murine model of chronic liver disease. J Cell Mol Med (2017) 0.75
Liver fibrosis. J Clin Invest (2005) 17.27
Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98
Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest (2005) 8.58
Role of integrins in cell invasion and migration. Nat Rev Cancer (2002) 7.64
Liver cirrhosis. Lancet (2008) 6.11
Reversal of hepatic fibrosis -- fact or fantasy? Hepatology (2006) 2.81
Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol (2007) 2.64
Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis (2001) 2.42
Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J Clin Invest (1989) 2.41
Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology (2002) 2.38
Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol (2001) 1.98
Integrin signaling is critical for pathological angiogenesis. J Exp Med (2006) 1.91
Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol (2001) 1.90
Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology (2007) 1.88
Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology (2008) 1.79
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer (2003) 1.75
Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat. Gastroenterology (1997) 1.75
Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology (2008) 1.69
Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem (2006) 1.64
Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol (2005) 1.62
Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut (2003) 1.60
Engagement of alphavbeta3 integrin regulates proliferation and apoptosis of hepatic stellate cells. J Biol Chem (2004) 1.59
Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am J Pathol (1999) 1.58
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs (2008) 1.56
Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res (2007) 1.55
Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood (2006) 1.40
Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem (2006) 1.40
Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology (2006) 1.36
Cirrhosis reversal: a duel between dogma and myth. J Hepatol (2004) 1.34
Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins. J Med Chem (2002) 1.31
Microvessel count predicts survival in uveal melanoma. Cancer Res (1996) 1.27
Analysis of liver repair mechanisms in Alagille syndrome and biliary atresia reveals a role for notch signaling. Am J Pathol (2007) 1.26
Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Mol Life Sci (2003) 1.24
A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin Exp Metastasis (2004) 1.23
Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol (2007) 1.19
Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol (2004) 1.13
Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis. Curr Opin Nephrol Hypertens (2003) 1.12
A novel, simple method of functional spleen volume calculation by liver-spleen scan. J Nucl Med (1999) 1.06
Smooth muscle cell matrix metalloproteinase production is stimulated via alpha(v)beta(3) integrin. Arterioscler Thromb Vasc Biol (2000) 1.04
Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol (2003) 1.03
Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. J Hepatol (2006) 1.03
Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. J Hepatol (2005) 1.02
Endothelial progenitor cell transplantation improves the survival following liver injury in mice. Gastroenterology (2006) 1.02
Molecular pathogenesis of alcohol-induced hepatic fibrosis. Alcohol Clin Exp Res (2005) 1.01
Hypoxia potentiates transforming growth factor-beta expression of hepatocyte during the cirrhotic condition in rat liver. Liver Int (2004) 0.98
Angiogenic cell therapy for hepatic fibrosis. Med Mol Morphol (2006) 0.97
Role of Kupffer cells in gut ischemia/reperfusion-induced hepatic microvascular dysfunction in mice. Hepatology (1997) 0.95
Beta3 integrin deficiency promotes cardiac hypertrophy and inflammation. J Mol Cell Cardiol (2006) 0.95
Matrix metalloproteinases and angiogenesis. Curr Opin Nephrol Hypertens (2002) 0.93
Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist. Mol Cancer Ther (2005) 0.93
Increased invasive potential and up-regulation of MMP-2 in MDA-MB-231 breast cancer cells expressing the beta3 integrin subunit. Int J Oncol (2007) 0.92
Macrophage beta3 integrin suppresses hyperlipidemia-induced inflammation by modulating TNFalpha expression. Arterioscler Thromb Vasc Biol (2007) 0.89
Either integrin subunit beta1 or beta3 is involved in mediating monocyte adhesion, IL-1beta protein and mRNA expression in response to surfaces functionalized with fibronectin-derived peptides. J Biomater Sci Polym Ed (2007) 0.87
Vascular integrin beta 3 and its relation to pulmonary metastasis of colorectal carcinoma. Anticancer Res (2001) 0.85
Angiostatin inhibits experimental liver fibrosis in mice. Int J Colorectal Dis (2004) 0.80
Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science (2002) 7.87
Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology (2004) 6.14
Herbal hepatotoxicity. J Hepatol (2005) 3.98
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57
Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer (2007) 3.36
Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest (2008) 2.89
Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. J Exp Med (2012) 2.58
Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology (2012) 2.58
Structure and mechanics of integrin-based cell adhesion. Curr Opin Cell Biol (2007) 2.48
Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology (2009) 2.16
Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection. J Hepatol (2012) 2.07
Update on serologic testing in celiac disease. Am J Gastroenterol (2010) 2.07
Three-dimensional EM structure of the ectodomain of integrin {alpha}V{beta}3 in a complex with fibronectin. J Cell Biol (2005) 1.97
The incidence and clinical spectrum of refractory celiac disease in a north american referral center. Am J Gastroenterol (2011) 1.96
Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer Biol Ther (2008) 1.89
Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. Gastroenterology (2011) 1.85
Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol (2007) 1.82
The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol (2009) 1.77
Non-Celiac Gluten sensitivity: the new frontier of gluten related disorders. Nutrients (2013) 1.74
Failure of fibrotic liver regeneration in mice is linked to a severe fibrogenic response driven by hepatic progenitor cell activation. Am J Pathol (2013) 1.73
Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol (2010) 1.73
Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry (2003) 1.69
Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology (2008) 1.69
A novel adaptation of the integrin PSI domain revealed from its crystal structure. J Biol Chem (2004) 1.68
Crystal structure of the complete integrin alphaVbeta3 ectodomain plus an alpha/beta transmembrane fragment. J Cell Biol (2009) 1.68
Serum hyaluronate correlates with histological progression in alcoholic liver disease. Eur J Gastroenterol Hepatol (2003) 1.64
Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol (2005) 1.62
Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice. Hepatology (2011) 1.61
Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology (2013) 1.59
A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. Clin Sci (Lond) (2011) 1.59
DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab (2013) 1.55
Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma. BMC Cancer (2009) 1.54
Distinct, alcohol-modulated effects of PNPLA3 genotype on progression of chronic hepatitis C. J Hepatol (2011) 1.52
[Prevalence of circulating autoantibodies in healthy individuals]. Med Klin (Munich) (2002) 1.52
Mortality excess in individuals with elevated IgA anti-transglutaminase antibodies: the KORA/MONICA Augsburg cohort study 1989-1998. Eur J Epidemiol (2006) 1.51
Pathomechanisms in celiac disease. Int Arch Allergy Immunol (2003) 1.51
Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol (2009) 1.50
alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis (2003) 1.48
Serum connective tissue markers as predictors of advanced fibrosis in patients with chronic hepatitis B and D. Turk J Gastroenterol (2011) 1.48
Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem (2006) 1.47
Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol (2008) 1.47
Nuclear and cytoplasmic AID in extrafollicular and germinal center B cells. Blood (2006) 1.46
Endoscopic ultrasound-guided endoscopic necrosectomy of the pancreas: is irrigation necessary? Surg Endosc (2011) 1.46
EUS-guided alcohol ablation of an insulinoma. Gastrointest Endosc (2006) 1.45
New insights into the structural basis of integrin activation. Blood (2003) 1.45
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol (2003) 1.45
Elevated liver regeneration in response to pharmacological reduction of elevated portal venous pressure by terlipressin after partial hepatectomy. Transplantation (2014) 1.44
Celiac crisis is a rare but serious complication of celiac disease in adults. Clin Gastroenterol Hepatol (2010) 1.40
Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem (2006) 1.40
Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages. PLoS One (2013) 1.40
Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer (2009) 1.39
Acupuncture and moxibustion in the treatment of ulcerative colitis: a randomized controlled study. Scand J Gastroenterol (2006) 1.38
Coming to grips with integrin binding to ligands. Curr Opin Cell Biol (2002) 1.38
Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut (2012) 1.37
Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-beta(1)-induced fibrogenesis in skin fibroblasts. Exp Cell Res (2002) 1.36
Lack of evidence for an association of Epstein-Barr virus infection with breast carcinoma. Breast Cancer Res (2002) 1.36
EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol (2005) 1.35
Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol (2009) 1.34
Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis. J Gastroenterol Hepatol (2010) 1.33
Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res (2003) 1.33
Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res (2006) 1.32
Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol (2008) 1.31
World Gastroenterology Organisation global guidelines on celiac disease. J Clin Gastroenterol (2013) 1.29
Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol (2004) 1.28
Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma. Int J Cancer (2011) 1.28
Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol (2006) 1.27
Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study. Digestion (2004) 1.26
The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol (2002) 1.25
A simple validated gluten-free diet adherence survey for adults with celiac disease. Clin Gastroenterol Hepatol (2009) 1.24
HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB. J Biol Chem (2010) 1.24
Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology (2005) 1.24
Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol (2006) 1.21
The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis. Hepatology (2009) 1.21
Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells. Hepatology (2010) 1.20
Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: prognostic impact may depend on type of treatment and stage of disease. Oral Oncol (2009) 1.18
Pathomechanisms in celiac disease. Best Pract Res Clin Gastroenterol (2005) 1.18
Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol (2012) 1.18
Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol Gastrointest Liver Physiol (2010) 1.17
A role for low hepatic copper concentrations in nonalcoholic Fatty liver disease. Am J Gastroenterol (2010) 1.15
CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res (2008) 1.15
Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma. J Pathol (2004) 1.14
Keratin variants associate with progression of fibrosis during chronic hepatitis C infection. Hepatology (2006) 1.14
Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J Hepatol (2003) 1.14
Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol (2005) 1.13
Factors that influence adherence to a gluten-free diet in adults with celiac disease. Dig Dis Sci (2008) 1.12
Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis. World J Gastroenterol (2010) 1.12